Home
About
Overview
Sharing Data
ORCID
Help
History (33)
RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.
Integration of Substance Abuse Treatment Organizations into Accountable Care Organizations: Results from a National Survey.
Prospective surveillance of D- recipients of D+ apheresis platelets: alloimmunization against D is not detected.
Plasmodium falciparum gametocyte carriage in longitudinally monitored incident infections is associated with duration of infection and human host factors.
Discontinuation of rivaroxaban: filling in the gaps.
See All 33 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Discontinuation of rivaroxaban: filling in the gaps.
Reynolds MR. Discontinuation of rivaroxaban: filling in the gaps. J Am Coll Cardiol. 2013 Feb 12; 61(6):659-60.
View in:
PubMed
subject areas
Atrial Fibrillation
Blood Coagulation
Female
Humans
Male
Morpholines
Risk Assessment
Rivaroxaban
Stroke
Thiophenes
Thromboembolism
Warfarin
authors with profiles
Matthew R Reynolds MD, MSc